These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10155597)

  • 1. Paclitaxel and docetaxel. Innovation, but at what cost?
    Lønning PE
    Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
    Brown RE; Hutton J
    Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE; Hutton J; Burrell A
    Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) for advanced breast cancer.
    Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
    [No Abstract]   [Full Text] [Related]  

  • 7. Docetaxel.
    Leahy M; Howell A
    Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Taxoids in ovarian and breast carcinoma: the role of the medical profession and the government].
    Slee PH; Eliel MR; Nortier JW; Rodenburg CJ
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):502-4. PubMed ID: 9623094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
    Langer-Nitsche C; Lück HJ; Heilmann M
    Acta Oncol; 2000; 39(8):1001. PubMed ID: 11206991
    [No Abstract]   [Full Text] [Related]  

  • 10. Docetaxel. A review of its role in breast cancer treatment.
    Antoine EC; Rixe O; Auclerc G; Weil M; Khayat D
    Am J Clin Oncol; 1997 Aug; 20(4):429-32. PubMed ID: 9256905
    [No Abstract]   [Full Text] [Related]  

  • 11. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
    Camidge DR; Kunkler IH
    Clin Oncol (R Coll Radiol); 2000; 12(4):272-3. PubMed ID: 11005698
    [No Abstract]   [Full Text] [Related]  

  • 12. Taxoids: new weapons against cancer.
    Nicolaou KC; Guy RK; Potier P
    Sci Am; 1996 Jun; 274(6):94-8. PubMed ID: 8643952
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fulminant hepatocellular necrosis following administration of docetaxel].
    Tomassini E; Muhizi J; al Raheb K; Steinbach G; Bemer M; Platini C
    Presse Med; 2001 Apr; 30(13):634. PubMed ID: 11346902
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current developments in use of docetaxel (taxotere) in gynecologic oncology].
    Jackisch C
    Med Klin (Munich); 1998 Sep; 93 Suppl 3():4-15. PubMed ID: 9796219
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to dexamethasone in patients with fluid retention after docetaxel.
    Chan S; Winterbottom L; Gardner S
    Lancet; 1996 May; 347(9013):1486-7. PubMed ID: 8676655
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel.
    Hofer S; Hunziker S; Tornillo L; Ludwig CU
    Ann Oncol; 2003 Feb; 14(2):340. PubMed ID: 12562665
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
    Westermann AM; ten Bokkel Huinink WW; Rodenhuis S
    Ann Oncol; 1996 Jan; 7(1):104. PubMed ID: 9081381
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost utility in second-line metastatic breast cancer.
    Berdeaux G; Hurteloup P
    Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
    [No Abstract]   [Full Text] [Related]  

  • 19. Docetaxel-induced subungual hemorrhage.
    Vanhooteghem O; André J; Vindevoghel A; Vandenbossche L; Vandeveire A; Song M
    Dermatology; 1997; 194(4):419-20. PubMed ID: 9252781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of taxane therapy.
    Yee GC
    Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.